OverviewSuggest Edit

Cyclerion Therapeutics is a biopharmaceutical company specializing in soluble guanylate cyclase (sGC) pharmacology. It discovers, develops and commercializes treatments for serious and orphan diseases. The company designs sGC stimulators with distinct pharmacologic and biodistribution properties that preferentially enhance nitric oxide-cGMP.
TypePublic
Founded2019
HQEly, GB
Websitecyclerion.com

Latest Updates

Employees (est.) (Feb 2021)94
Share Price (Feb 2021)$3.8
Cybersecurity ratingBMore

Key People/Management at Cyclerion

Christopher Wright

Christopher Wright

Chief Medical Officer
Peter Hecht

Peter Hecht

Chief Executive Officer, Director
Andy Busch

Andy Busch

Chief Scientific Officer
Cheryl Gault

Cheryl Gault

Chief Operating Officer
Anjeza Gjino

Anjeza Gjino

Chief Financial Officer
Show more

Cyclerion Office Locations

Cyclerion has an office in Ely
Ely, GB (HQ)
Unit 3, Clive Court, Bartholomew's Walk, Cambridgeshire Business Park
Show all (1)

Cyclerion Financials and Metrics

Cyclerion Revenue

Market capitalization (26-Feb-2021)

130.4m

Closing stock price (26-Feb-2021)

3.8
Cyclerion's current market capitalization is $130.4 m.
Show all financial metrics

Cyclerion Cybersecurity Score

Cybersecurity ratingPremium dataset

B

88/100

SecurityScorecard logo

Cyclerion Online and Social Media Presence

Embed Graph

Cyclerion News and Updates

Cyclerion Therapeutics Announces Clinical and Scientific Advisory Boards

Leading experts in central nervous system (CNS) clinical development and translational sciences to advise company’s advancement of therapeutic pipeline candidates

Cyclerion to Participate in the 39th Annual J.P. Morgan Healthcare Conference and H.C. Wainwright BioConnect Conference

CAMBRIDGE, Mass., Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing innovative medicines for people with serious diseases of the central nervous system (CNS), today announced that it will present a corporate overvie…

Cyclerion Announces Leadership Transitions

Anjeza Gjino promoted to Chief Financial Officer; Bill Huyett to transition to Strategic Advisor

Cyclerion Announces Phase 2 STRONG-SCD Study Results in Patients with Sickle Cell Disease

Study results do not support further internal development Study results do not support further internal development

Cyclerion Announces Positive Data from IW-6463 CNS Translational Pharmacology Study in Healthy Elderly Subjects

Showed significant improvements in neurophysiological and objective performance measures associated with age-related cognitive decline and neurodegenerative diseases

Cyclerion to Participate at Upcoming September 2020 Investor Conferences

CAMBRIDGE, Mass., Sept. 04, 2020 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that Company mana…
Show more

Cyclerion Frequently Asked Questions

  • When was Cyclerion founded?

    Cyclerion was founded in 2019.

  • Who are Cyclerion key executives?

    Cyclerion's key executives are Christopher Wright, Peter Hecht and Andy Busch.

  • How many employees does Cyclerion have?

    Cyclerion has 94 employees.

  • Who are Cyclerion competitors?

    Competitors of Cyclerion include Reata Pharmaceuticals, Ironwood Pharmaceuticals and Biogen.

  • Where is Cyclerion headquarters?

    Cyclerion headquarters is located at Unit 3, Clive Court, Bartholomew's Walk, Cambridgeshire Business Park, Ely.

  • Where are Cyclerion offices?

    Cyclerion has an office in Ely.

  • How many offices does Cyclerion have?

    Cyclerion has 1 office.